Cost-effectiveness of video-observed therapy for ambulatory management of active tuberculosis during the COVID-19 pandemic in a high-income country

• Published in: International journal of infectious diseases Vol. 113; pp. 271 - 278
• Main Authors: Fekadu, Ginenus, Jiang, Xinchan, Yao, Jiaqi, You, Joyce H.S.
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.12.2021; The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases; Elsevier
• Subjects: Adult; Antitubercular Agents - therapeutic use; Cost-Benefit Analysis; Cost-effectiveness; COVID-19; COVID-19 pandemic; Disability-Adjusted Life Years; High income; Humans; Pandemics; SARS-CoV-2; Tuberculosis; Tuberculosis - epidemiology; Video-observed therapy; COVID-19 pandemic; High income; Tuberculosis; Video-observed therapy; Cost-effectiveness

•The USA is a high-income country with a low tuberculosis (TB) burden.•The coronavirus disease 2019 pandemic suspended directly observed therapy (DOT) for patients with TB.•Suspension of DOT worsened treatment outcomes and increased the cost of TB.•Video-observed therapy was cost-effective for TB du...